558 related articles for article (PubMed ID: 30125215)
21. Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease.
Alcoceba M; Stewart JP; García-Álvarez M; Díaz LG; Jiménez C; Medina A; Chillón MC; Gazdova J; Blanco O; Díaz FJ; Peñarrubia MJ; Fernández S; Montes C; Cabero A; Caballero MD; García-Sanz R; González M; González D; Tamayo P; Gutiérrez NC; García-Sancho AM; Sarasquete ME
Br J Haematol; 2024 May; ():. PubMed ID: 38811363
[TBL] [Abstract][Full Text] [Related]
22. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.
Baumgartner JM; Raymond VM; Lanman RB; Tran L; Kelly KJ; Lowy AM; Kurzrock R
Ann Surg Oncol; 2018 Aug; 25(8):2400-2408. PubMed ID: 29948422
[TBL] [Abstract][Full Text] [Related]
23. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
24. Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma.
Lakhotia R; Melani C; Dunleavy K; Pittaluga S; Saba N; Lindenberg L; Mena E; Bergvall E; Lucas AN; Jacob A; Yusko E; Steinberg SM; Jaffe ES; Wiestner A; Wilson WH; Roschewski M
Blood Adv; 2022 Apr; 6(8):2667-2680. PubMed ID: 35143622
[TBL] [Abstract][Full Text] [Related]
25. Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study.
Rivas-Delgado A; Nadeu F; Enjuanes A; Casanueva-Eliceiry S; Mozas P; Magnano L; Castrejón de Anta N; Rovira J; Dlouhy I; Martín S; Osuna M; Rodríguez S; Simó M; Pinyol M; Baumann T; Beà S; Balagué O; Delgado J; Villamor N; Setoain X; Campo E; Giné E; López-Guillermo A
Clin Cancer Res; 2021 Jan; 27(2):513-521. PubMed ID: 33122345
[TBL] [Abstract][Full Text] [Related]
26. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
Kwok M; Wu SP; Mo C; Summers T; Roschewski M
Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
Strijker M; Soer EC; de Pastena M; Creemers A; Balduzzi A; Beagan JJ; Busch OR; van Delden OM; Halfwerk H; van Hooft JE; van Lienden KP; Marchegiani G; Meijer SL; van Noesel CJ; Reinten RJ; Roos E; Schokker S; Verheij J; van de Vijver MJ; Waasdorp C; Wilmink JW; Ylstra B; Besselink MG; Bijlsma MF; Dijk F; van Laarhoven HW
Int J Cancer; 2020 Mar; 146(5):1445-1456. PubMed ID: 31340061
[TBL] [Abstract][Full Text] [Related]
28. The molecular tumor burden index as a response evaluation criterion in breast cancer.
Yi Z; Ma F; Rong G; Liu B; Guan Y; Li J; Sun X; Wang W; Guan X; Mo H; Wang J; Qian H; Xu B
Signal Transduct Target Ther; 2021 Jul; 6(1):251. PubMed ID: 34230452
[TBL] [Abstract][Full Text] [Related]
29. A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression.
Sun R; Zheng Z; Wang L; Cheng S; Shi Q; Qu B; Fu D; Leboeuf C; Zhao Y; Ye J; Janin A; Zhao WL
Mol Oncol; 2021 Jan; 15(1):246-261. PubMed ID: 33107145
[TBL] [Abstract][Full Text] [Related]
30. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma.
Sarkozy C; Huet S; Carlton VE; Fabiani B; Delmer A; Jardin F; Delfau-Larue MH; Hacini M; Ribrag V; Guidez S; Faham M; Salles G
Oncotarget; 2017 Jan; 8(5):8765-8774. PubMed ID: 28060738
[TBL] [Abstract][Full Text] [Related]
31. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
Meriranta L; Alkodsi A; Pasanen A; Lepistö M; Mapar P; Blaker YN; Jørgensen J; Karjalainen-Lindsberg ML; Fiskvik I; Mikalsen LTG; Autio M; Björkholm M; Jerkeman M; Fluge Ø; Brown P; Jyrkkiö S; Holte H; Pitkänen E; Ellonen P; Leppä S
Blood; 2022 Mar; 139(12):1863-1877. PubMed ID: 34932792
[TBL] [Abstract][Full Text] [Related]
32. ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial.
Audinot B; Drubay D; Gaspar N; Mohr A; Cordero C; Marec-Bérard P; Lervat C; Piperno-Neumann S; Jimenez M; Mansuy L; Castex MP; Revon-Riviere G; Marie-Cardine A; Berger C; Piguet C; Massau K; Job B; Moquin-Beaudry G; Le Deley MC; Tabone MD; Berlanga P; Brugières L; Crompton BD; Marchais A; Abbou S
Ann Oncol; 2024 Jun; 35(6):559-568. PubMed ID: 38142939
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
Lakhotia R; Roschewski M
Br J Haematol; 2021 Jun; 193(5):867-881. PubMed ID: 33550600
[TBL] [Abstract][Full Text] [Related]
34. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
Iijima Y; Hirotsu Y; Amemiya K; Ooka Y; Mochizuki H; Oyama T; Nakagomi T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Goto T; Miyashita Y; Omata M
Eur J Cancer; 2017 Nov; 86():349-357. PubMed ID: 29078173
[TBL] [Abstract][Full Text] [Related]
35. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
36. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
37. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma.
Gao R; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Yang T; Xu W
Int J Cancer; 2018 Oct; 143(8):1884-1895. PubMed ID: 29744861
[TBL] [Abstract][Full Text] [Related]
38. Updates on Circulating Tumor DNA Assessment in Lymphoma.
Darrah JM; Herrera AF
Curr Hematol Malig Rep; 2018 Oct; 13(5):348-355. PubMed ID: 30136210
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.
Roschewski M; Dunleavy K; Pittaluga S; Moorhead M; Pepin F; Kong K; Shovlin M; Jaffe ES; Staudt LM; Lai C; Steinberg SM; Chen CC; Zheng J; Willis TD; Faham M; Wilson WH
Lancet Oncol; 2015 May; 16(5):541-9. PubMed ID: 25842160
[TBL] [Abstract][Full Text] [Related]
40. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
Prochazka KT; Melchardt T; Posch F; Schlick K; Deutsch A; Beham-Schmid C; Weiss L; Gary T; Neureiter D; Klieser E; Greil R; Neumeister P; Egle A; Pichler M
Br J Cancer; 2016 Nov; 115(10):1264-1272. PubMed ID: 27764838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
